NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
Clinical Trials
4 trialsNCT05233332 2023-05-31
mCRC
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT03727763 2021-08-19
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
Phase 2 Unknown